Benefit of baricitinib for treatment of patients with moderately to severely active SLE is unclear

The work of a clinician-scientist often feels like two steps forward, one step back. Just ask Professor Eric Morand, Head of the School of Clinical Sciences at Monash University.

Leave A Comment

Your email address will not be published. Required fields are marked *